Form 4 for ELVN Enliven Therapeutics, Inc.
Accepted 2023-09-26 00:00:00 ET · period of report 2023-09-25 · accession 0001209191-23-050616 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2023-09-26 | 2023-09-25 | ELVN | Kintz Samuel | Pres, CEO, Dir | S - Sale+OE | $13.81 | -12.0K | 0 | -100% | -$165.7K |
| D | 2023-09-26 | 2023-09-25 | ELVN | Kintz Samuel | Pres, CEO, Dir | M - OptEx | $1.12 | +12.0K | 12.0K | New | +$13.4K |
| D | 2023-09-26 | 2023-09-25 | ELVN | Kintz Samuel | Pres, CEO, Dir | M - OptEx | $0.00 | -12.0K | 332.6K | -3% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-09-25 | S | D | 12,000 | $13.81 | 0 | D | — | — | (F2) This transaction was executed in multiple trades at prices ranging from $13.11 to $14.095. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price. |
| 2 | Common | Common Stock | 2023-09-25 | M | A | 12,000 | $1.12 | 12,000 | D | — | — | |
| 3 | Derivative | Stock Option (right to buy) | 2023-09-25 | M | D | 12,000 | $0.00 | 332,550 | D | $1.12 · — to 2030-06-15 | 12,000 Common Stock | (F6) The option, originally for 344,550 shares, is subject to an early exercise provision and is immediately exercisable. Shares subject to the option vest in 48 equal monthly installments beginning on May 3, 2020. |